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1. Introduction
Diabetes mellitus is one of the most prevalent chronic diseases in children. Diabetes mellitus
is classified into four major types. Type 1, type 2, gestational, and other specific types. Type
1 diabetes (T1D) is caused by autoimmune destruction of the insulin-producing beta cells of
the pancreas. Type 2 diabetes (T2D) results from a combination of insulin resistance and be‐
ta cell insulin secretory defect. The rising prevalence of childhood obesity has made it more
difficult to differentiate between these types of diabetes in children. There is a new expres‐
sion of diabetes in children known as double diabetes, or hybrid diabetes. This is a clinical
state where both T1D and T2D co-exist in the same individual as shown in Figure 1 below.
Childhood obesity is one of the most serious public health challenges of the 21st century [1].
According to the National Health and Nutrition Examination Survey data, about 16% of
children and adolescents in the United States have a body mass index (BMI) (kg/m2) ≥95th
percentile for age and gender [2]. Body mass index of >95th percentile is classified as over‐
weight by the Center for Disease Control and Prevention [3,4], and as obesity by European
criteria [5].
The prevalence of obesity has tripled in the past three decades [6] among male and female
adolescents, and across different racial and ethnic groups [6-8]. There has also been a paral‐
lel increase in the prevalence of many obesity-related co-morbid conditions [9] such as T2D,
dyslipidemia, hypertension, obstructive sleep apnea, poor quality of life and mortality in
adulthood [10-13]. Although obesity is associated primarily with T2D due to insulin resist‐
ance, [14], it may also impact T1D morbidity.
T1D is caused by autoimmune destruction of the beta cells of the pancreas leading to insuli‐
nopenia. It is sub-classified into 2 main categories- type 1A and 1B [15]. In type 1A, individ‐
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uals have one or more of the anti-islet cell (including glutamic acid decarboxylase, and
insulinoma antigen-2) or anti-insulin antibodies. In type 1B these antibodies are absent, but
the clinical and biochemical features are similar to 1A. T2D is characterized by insulin resist‐
ance and absence of diabetes-associated antibodies in serum.
A new subset of diabetes, called double diabetes is becoming increasingly prevalent as a re‐
sult of the epidemic of childhood obesity [16-18]. In double diabetes, elements of both T1D
and T2D co-exist. In this condition, individuals with T1D have insensitivity to insulin that is
most often associated with obesity; and individuals with T2D have antibodies against the
pancreatic beta cells [14] (Figure 1). Unlike T1D and T2D, there is no consensus on the thera‐
peutic modalities for double diabetes.
The incidence of both T1D and T2D is rising in children and adolescents [14]. Data from the
EURODIAB study indicate that the overall prevalence of T1D among young people under
15 years is increasing by greater than 3% each year, and by more than 6% a year in children
aged up to four years [19].Analysis of the 2002 to 2003 data from SEARCH for Diabetes in
Youth, a multicenter study funded by the Centers for Disease Control and Prevention and
the National Institutes of Health to examine T1D and T2D among children and adolescents
in the United States, showed that annually, about 15,000 youth in the United States are new‐
ly diagnosed with T1D, and about 3,700 youth with T2D. The reported rate of new cases
among youth was 19 per 100,000 each year for T1D, and 5.3 per 100,000 for T2D [20].
2. Prevalence
The prevalence of double diabetes is unknown [16]. However, reports show that about 25%
of children with T1D are either overweight or obese [21]. Other reports show that about 35%
of children and adolescents with T2D have at least one diabetes-associated antibody [22].
Some authors estimate that about one in three children and adolescents with newly diag‐
nosed diabetes has double diabetes. Pozzilli et al reported a prevalence of 4.96% in their un‐
published Italian cohort [1]. The major difficulty with establishing a prevalence rate for
double diabetes is that there are no precise definitions for the different types of diabetes pre‐
senting in youth [1]. This is because clinical phenotypes frequently overlap at onset of the
disease [1]. For example, obesity and ketoacidosis can be found in both T1D and T2D [23],
and the age of diagnosis is now a poorly differentiating factor [24]. In other cases, the clini‐
cal features of double diabetes are not apparent at diagnosis but evolve over time [18].
3. Etiology and pathophysiology
There are genetic, environmental and behavioral factors that affect the pathophysiological
processes of T1D and T2D in such as way to result in double diabetes. Obesity is the central
pathophysiological mechanism for double diabetes. Obesity may arise from genetic predis‐
position or from environmental factors such as the anabolic role of insulin injection in pa‐
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tients with T1D who fail to make the necessary healthy lifestyle changes that are
recommended for maintenance of normal weight.
3.1. Genetic factors
Unlike T1D where the MHC region of chromosome 6 accounts for approximately 40% of the
genetic risk of the disease in concert with other genes [25], and in T2D where genome-wide
association studies have identified approximately 50 genetic loci associated with T2D in lean
and obese individuals [26-28], there are no distinct genes that are unique to double diabetes.
However, it is believed that the major genes that are independently associated with suscept‐
ibility to either T1D (e.g., the MHC and cytotoxic T lymphocyte-associated antigen-4
(CTLA-4) [29] or T2D (e.g., the genes encoding adiponectin (APM1) and transcription factor
7-like 2 (TCF7L2) [30] can serve as genetic determinants for double diabetes, such that the
frequency of the major T1D genetic susceptibility gene (MHC) is reduced, whereas the ex‐
pression of the genes associated with T2D is enhanced [31].
Apart from the principal genetic determinants of T1D and T2D, there are a number of genes
that could potentially lead to an outcome of double diabetes by influencing the pathogenetic
processes operating in both T1D and T2D [32]. One of such genes resulting from a genetic
variance in insulin receptor substrate 1 (IRS-1) plays an important role in insulin resistance,
a key component of T2D, and also in β cell apoptosis which is associated with T1D [33].
High mobility group A1 (HMGA1) protein, a product of the Hmga1 gene has been identi‐
fied as a crucial effector in the control of glucose homeostasis, such that impaired HMGA1
function may contribute to the development of specific forms of diabetes [34]. HMGA1-defi‐
cient indiviuduals have reduced insulin receptor expression, reduced insulin signaling and
decreased insulin secretion similar to the phenotype of T2D [34].
3.2. Environmental and behavioral factors
The epidemic of childhood obesity has led to increased diagnosis of metabolic syndrome
and T2D in all children including those with existing T1D [35]. Obese or overweight chil‐
dren have been reported to develop T1D at younger ages than children of normal weight
[35]. The SEARCH for Diabetes in Youth Study [36] reported an obesity prevalence rate of
12.6% in US youth with T1D. The study also reported a higher prevalence of overweight sta‐
tus (BMI 85th – 95th percentile) among youth with T1D than in those without diabetes
(22.1% vs. 16.1%) (P<0.05). Some children with T1D have either a first- or second-degree rel‐
ative with T2D [1]. Furthermore, weight gain is prevalent in adolescents with T1D after at‐
tainment of adult height, which might further impair insulin sensitivity [37].
Therefore, several enviromental factors could lead to the development of double diabetes by
their influence on the disease processes of T1D and T2D. Many of the major genetic factors
involved in the etiopathogenesis of T2D appear to promote the development of the disease
through their influence on obesity and feeding behavior [38]. There is evidence that rapid
growth and obesity in early childhood might increase the risk of T1D [35,39]. The strong en‐
vironmental basis for this obesity pandemic and influence on feeding behavior was recently
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outlined in a World Health Organization Technical Report [40] which states that ‘Changes in
the world food economy have contributed to shifting dietary patterns, for example, in‐
creased consumption of energy-dense diets high in fat, particularly saturated fat, and low in
unrefined carbohydrates. These patterns are combined with a decline in energy expenditure
that is associated with sedentary lifestyle, motorized transport, labor-saving devices at
home, the phasing out of physically-demanding manual tasks in the workplace, and leisure
time that is preponderantly devoted to physically undemanding pastimes’. However, de‐
spite the established association between obesity and the increasing prevalence of T1D, it is
unclear how these environmental processes lead to β cell destruction.
Several mechanistic models have been proposed to explain this phenomenon. Some reports
have linked high titers of glutamic acid decarboxylase autoantibody to an increase in body
mass index (BMI) [41] which suggests that increased BMI might favor the development of
an autoimmune response towards β cells. This is in line with other reports indicating that a
combination of obesity and insulin resistance speeds up the process of beta cell destruction
[35,42]. Other proposed mechanisms for beta cell destruction include the the role of upregu‐
lation of autoimmune response by obesity-associated inflammatory cytokines, and hyper‐
leptinemia-associated T-cell activation [43,44].
Other researchers have proposed the following mechanism for obesity-induced insulin re‐
sistance : (a) the liberation of large amounts of non-esterified fatty acids by visceral fat
which stimulate neoglucogenesis in the liver and diminish glucose uptake in the muscles;
(b) the association of obesity with increased activity of the sympathetic nervous system,
which in combination with direct release of tumor necrosis factor, resistin and other adipo‐
cytokines contribute to insulin resistance; (c) the role of the accummulation of local intra‐
myocellular triglycerides on muscle insulin senstivity [45].
In additon to the above mechanistic models, several hypotheses have been advanced to ex‐
plain the association between obesity and rising prevlaence of T1D. The most prominent of
these hypotheses is the accelerator hypothesis which states that T1D and T2D are the same
disease state set in different genetic backgrounds [46]. It originally proposed three major fac‐
tors as the basis for the development of diabetes: genetic predisposition, insulin resistance
and intrinsic rate of beta cell loss. The accelerators have now been reduced to two without
altering the premise of the hypothesis [46]. The first is insulin resistance which is believed to
accelerate β-cell apoptosis while rendering them more immunogenic. It posits that insulin
resistance is the primary driver for the development of diabetes in a susceptible individual
and argues that insulin resistance increases through weight gain as does the rate of onset of
diabetes [47]. The second accelerator is the hierachy of responsive genes whose reactivity
modulates the gradient of β-cell declining function [46].
The central premise of the accelerator hypothesis is based on studies reporting rising inci‐
dence of obesity [6,48] and T1D in children [49,50]. These findings were strengthened by re‐
ports of an association between weight gain and an increased risk to develop diabetes
mellitus [51-53], as well as several reports from Europe indicating that an increasing number
of children are being diagnosed with T1D at an earlier age [54-58]. This hypothesis proposes
a direct cause and effect relationship between obesity and the development of both T1D and
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T2D, and states that as the population becomes heavier (fatter), diabetes appears earlier,
thus suggestive of a true acceleration rather than an incidental risk association [59].
The accelerator hypothesis is controversial because studies designed to prove its validity
have reached various conclusions [35,60-65]. Reports from the United Kingdom indicated a
relationship between younger age at diagnosis of T1D and higher body mass index (BMI) in
Middlesbrough [35], and Plymouth [64],but not in Birmingham [61]. Other European studies
of large cohorts of German and Austrian children with T1D supported the hypothesis
[62,63], although studies from Spain and Australia [66,67] did not. Two studies have been
conducted in the United States to examine this hypothesis. Dabelea et al [65] tested the hy‐
pothesis in six centers in the US (Cincinnati, Colorado, Hawaii, Seattle, South Carolina,
Southern California) and found a significant relationship between BMI standard deviation
score (SDS) and age at diagnosis only among patients with low C-peptide values at diagno‐
sis. Evertsen et al [50] reported a significant inverse relationship between age at diagnosis
and BMI SDS in their Wisconsin cohort. Thus, there is no consensus on the validity of the
hypothesis among children and adolescents with T1D in the United States.
4. Clinical features
Traditionally, a patient with the classic symptoms of diabetes which include polyuria, poly‐
dipsia, and polyphagia who also has a family history of T2D, obesity, acanthosis nigricans
and lack of both ketosis and diabetes-associated autoantibodies is considered to have T2D
[68]. On the other hand, patients with T1D are usually thought to be thin, may present with
ketosis, and have diabetes associated autoantibodies. [18] Patients with double diabetes pos‐
sess the features of both T1D and T2D which could present siimultaneously at the time of
diagnosis, or develop sequentially over time [18].
Features of Double Diabetes in Child or Adolescent with Pre-existingType 1 diabetes: The signs and
symptoms typical of T2D can develop gradually in a child or adolescent with pre-existing
T1D. The rate of the development of these features of increased metabolic load depends on
the individual’s genetic makeup and his or her degree of weight gain. These patients are
usually overweight or obese and require a high dose of insulin to maintain euglycemia be‐
cause of obesity-related insulin resistance [31,69]. Some of these patients may have hyper‐
tension, dyslipidemia, and poor diabetes control. Female adolescent patients may have
polycystic ovarian syndrome.
Features of Double Diabetes in Child or Adolescent with Pre-existing Type 2 diabetes: The presence
of increased ‘autoimmune load’ as marked by the presence of diabetes-associated autoanti‐
bodies in a child or adolescent with all of the typical clinical features of T2D - excess body
weight, acanthosis nigricans, high blood pressure, dyslipidemia, polycystic ovary syn‐
drome, positive family history of T2D, belonging to ethnic/racial minority group – is consis‐
tent with a diagnosis of double diabetes [31,69].
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5. Diagnosis
There is the need to formulate universal diagnostic criteria to facilitate the recognition of
double diabetes either at the time of onset of hyperglycemia or in the course of the disease
process. Pozzilli et al [16,31] recently introduced the concept of ‘metabolic load’ to describe
the features of T2D and ‘autoimmune load’ to describe the features of T1D. They stated that
in an obese child or adolescent with hyperglycemia, an increased ‘metabolic load’ and a re‐
duced ‘autoimmune load’ are features of double diabetes (Figure 1). Based on this principle,
they advanced the following clinical and biochemical guidelines to facilitate the diagnosis of
double diabetes:
i. The presence of clinical features of T2D, hypertension, dyslipidemia, increased
body mass index with increased cardiovascular risk, compared with children with
classical T1D. Family history for T2D and T1D might be present.
ii. The presence of a reduced number of clinical features typical of T1D, such as
weight loss, polyuria and polydipsia, development of ketoacidosis; insulin therapy
is not the first line of therapy, by contrast to the situation in subjects with classical
T1D.
iii. The presence of autoantibodies to islet cells, although with a reduced number and
titer compared with T1D, and probably a reduced risk associated with the MHC
locus compared with subjects with T1D. As compared with T1D, where insulin re‐
sistance and obesity are not common features, double diabetes is always character‐
ized by an obese phenotype, with the additional coexistence of β cell
autoimmunity.
Figure 1. The relationship between T1D, T2D and Double Diabetes, TID = type 1 diabetes, T2D = type 2 diabetes, FBG
= fasting blood glucose, 2HPP = 2 hour post prandial glucose level; BMI = body mass index; Abs = antibodies
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6. Treatment
There is no consensus on the best therapeutic regimen for double diabetes. However, be‐
cause insulin resistance is central to the pathophysiological mechanism of double diabetes,
optimal management of this condition necessitates the addition of insulin sensitizers to the
patient’s therapeutic regimen under appropriate clinical circumstances [18]. Intensification
of lifestyle modification strategies should be encouraged to maintain normal weight and at‐
tenuate insulin resistance. Finally, because these patients require increased doses of insulin
to maintain euglycemia, it is necessary to develop an insulin titration regimen that would
ensure adequate glycemic control.
6.1. The burden of poor glycemic control in children and adolescents
The availability of insulin analogs and diabetes monitoring devices has improved diabetes
care around the world. However, according to recent studies, the prevalence of poorly-con‐
trolled diabetes in youth is still high [70]. This poor glycemic control predisposes the youth
to acute and chronic complications of diabetes.
A report by the SEARCH for Diabetes in Youth Study group showed that a high proportion
of youth with diabetes had high HbA1c values, with 17% of the youth with TIDM, and 27%
of those with T2D showing poor control, defined as HbA1c ≥ 9.5% [70]. The American Dia‐
betes Association target values for HbA1c in relation to age are as follows: 7.5-8.5% at age <
6 years, <8% at age 6-12 years, <7.5% at age 13-18 years, and <7.0% at age 19+ years [68].
Thus only a minority of children and adolescents meet the recommended glycemic targets.
The physiological factors that contribute to poor glycemic control in youth are in part relat‐
ed to the hormonal changes in puberty. Puberty is associated with relative insulin resistance,
reflected in a two- to threefold increase in the peak insulin response to oral or intravenous
glucose [71]; insulin-mediated glucose disposal is approximately 30% lower in adolescents
than in prepubertal children or young adults [72]. This physiologic insulin resistance of pub‐
erty is of minimal consequence in the presence of adequate beta-cell function [73]. The cause
of this physiologic resistance is likely the transitory increased activity of the growth hor‐
mone-insulin growth factor axis, as well as sex steroids, which coincides with the physiolog‐
ic insulin resistance of adolescence [74] and act as counter-regulatory hormones. As a result
of these physiological changes, insulin dosages are often increased to overcome the resist‐
ance to insulin, but metabolic control still frequently worsens during the later stages of pu‐
bertal development [37].
6.2. Alternative therapeutic strategies
The increasing insulin resistance and deterioration of glycemic control in adolescents create
a great need for alternative therapeutic strategies in adolescents with T1D. One such strat‐
egy is the addition of a drug that improves insulin sensitivity such as metformin, a bigua‐
nide that acts principally by increasing insulin sensitivity in the liver by inhibiting hepatic
gluconeogenesis and thereby reducing hepatic glucose production [75]. Other minor mecha‐
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nisms include decreasing fatty acid oxidation and intestinal glucose absorption [76], and in‐
creasing peripheral insulin sensitivity by enhancing glucose uptake in the muscles [77].
Metformin has mainly been used in adult patients with T2D and several studies have shown
beneficial effects on body weight, blood lipid levels and metabolic control [78-80]. Random‐
ized controlled trials with metformin in adolescents with T2D reported an improvement in
fasting plasma glucose level [81]. However, there have been conflicting reports from studies
in adolescents with T1D [75-77,82,83]. The benefit was transient in one study [83] and nega‐
tive in another [82]. The main drawback of these studies was the small sample size and lack
of reporting on long term benefit and safety of adjunctive therapy in many of them [84].
Evidence for the coexistence of insulin resistance and insulin deficiency in childhood-on‐
set  T1D  adults  has  been  demonstrated  by  the  insulin-glucose  clamp  technique  [85,86].
Furthermore, two randomized, placebo-controlled trials have investigated the role of ad‐
junctive metformin therapy in adolescents with T1D. In a randomized placebo controlled
trial  in  children  with  T1D  who  were  treated  for  3  months  with  adjunctive  metformin,
Sarnblad et  al  [77]  reported a  significant  decrease  in  A1c  from 9.6% to  8.7%(p<0.05)  in
the metformin group, compared to 9.5 to 9.2% (p=NS) in the placebo group. In another
study, Hamilton et al [75] reported an HbA1c 0.6% lower in the metformin group than in
the placebo group (P<0.035),  after  3  months of  therapy.  Mean HbA1c at  the end of  the
study was decreased by 0.3% in the metformin group, while it  increased by 0.3% in the
placebo  group  (p=0.03).  Both  studies  reported  no  difference  in  mean  body  mass  index
and  serum  lipids  in  the  metformin  versus  placebo  group  after  3  months  of  therapy.
Hamilton et al [75] reported no significant changes in mean insulin sensitivity, measured
by frequently sampled glucose after intravenous glucose tolerance test, after 3 months of
metformin therapy in the metformin versus placebo group. Sarnblad et al [77], using hy‐
perinsulinemic  euglycemic  clamp  study,  demonstrated  no  significant  change  in  insulin
sensitivity after 3 months between the groups, but they did report an increase in insulin
sensitivity in the metformin group during the study (P<0.05). Hamilton et al [75] report‐
ed a significant  change in the mean daily insulin dose in the metformin group in com‐
parison  to  the  placebo  group  after  3  months  of  metformin  therapy  of  -0.14  vs.  0.02,
P=0.01.  However,  Sarnblad [77]  did not  find a significant  difference in the daily insulin
dosage  between  the  metformin  and  placebo  groups  after  3  months  of  therapy  (1.1  vs.
1.3).
The two randomized, controlled studies by Hamilton and Sarnblad did not categorically re‐
cruit children and adolescents with double diabetes. This is important because this sub-set
of diabetic youth is known to be insulin resistant and may require a careful titration of insu‐
lin doses. Adjunctive metformin therapy to achieve glycemic control may also be more effec‐
tive in this subset of diabetes patients.
Furthermore, even though these randomized controlled trials were designed to investigate
the effectiveness of adjunctive metformin therapy compared to insulin therapy alone, they
were not designed to compare metformin adjunctive therapy to protocol-driven, optimized
insulin therapy. Neither study demonstrated a strong head-to-head comparison of adjunc‐
tive metformin to patient-directed, treat to target insulin regimen to ensure optimal insulin
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delivery during the study. Such a comparison is critical because poor glycemic control con‐
tributes to insulin resistance [87] as there is an inverse relationship between glycemic control
(as determined by HbA1c) and insulin sensitivity (estimated by glucose infusion rate during
euglycemic-hyperinsulinemic clamp) [88].
6.3. The need for an insulin titration regimen for double diabetes
In general, patients with double diabetes are overweight or obese and the resultant insulin
resistance increases their insulin requirement [1]. However, in addition to requiring a high
insulin dose, evidence suggests that many patients often do not have insulin doses titrated
sufficiently to achieve target levels of glucose control [89,90]. These patients remain on sub‐
optimal doses of insulin and fail to reach treatment targets [91]. In a recent study Blonde et
al [91] demonstrated the efficacy of algorithm-guided, patient titration of once daily long
acting insulin in normalizing HbA1c in adult patients with T2D. They conducted a 20-week,
randomized, controlled, open label, multicenter, parallel-group study comparing the safety
and efficacy of insulin detemir administered once daily in combination with oral antidiabet‐
ic agents when titrated to two fasting plasma glucose targets ( 3.0-5.0 mmol/L versus 4.4.-6.1
mmol/L) for the treatment of T2D in adults. In that study, fasting plasma glucose level de‐
creased throughout the first 8 weeks of the study and then generally remained flat for each
treatment group. The combined treatment groups achieved a mean HbA1c level of 6.9% at
the end of the study. There were significant reductions in HbA1c in both titration groups: in
the 3.9-5.0 mmol/L fasting plasma glucose target group, HbA1c values decreased from a
baseline mean of 8% to 6.8% at 20 weeks. In the 4.4-6.1 mmol/L fasting plasma glucose target
group, HbA1c values decreased from a 7.9% at baseline to 7.0% at 20 weeks. Overall rates of
hypoglycemia episodes were low and were comparable between treatment groups: 7.73 and
5.27 events/subject/year for the 3.9-5 mmol/L and 4.4-6.1 mmol/L groups, respectively. Mean
weight changes from baseline to the end of the study were small and did not differ signifi‐
cantly between groups.
Our group is conducting a randomized control trial to explore the role of protocol-driven
treat-to-target regimen in children and adolescents with double diabetes. Given the rising
prevalence of obesity in the general population we speculate that many children with T1D
will eventually develop double diabetes. Thus, it is timely to devise an appropriate manage‐
ment protocol to treat this burgeoning sub-population. Our aim is to primarily study this
group of patients to determine the role of protocol-driven, treat-to-target regimen alone or
in combination with metformin therapy in their care. Metformin is approved by the Food
and Drug Administration for use in children with T2D, and recently it has been recommend‐
ed that metformin added to insulin therapy might be used in clinical practice in adolescents
with T1D who are poorly controlled and show evidence of insulin resistance (double diabe‐
tes) as noted in T2D [84]. Given the conflicting reports on the efficacy of adjunctive metfor‐
min therapy in adolescents with T1D, this double blind, randomized, placebo controlled
trial will demonstrate the effect of meformin on HbA1c reduction under optimized insulin
titration regimen. Secondly, we will investigate whether a titrated insulin regimen alone
would have a superior-, or similar effect to combined metformin and titrated insulin regi‐
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men in children and adolescents with double diabetes and how this modality of treatment
compares to standard insulin therapy.
Blonde et al [91] demonstrated that self-titration regimens facilitate empowerment of pa‐
tients, allowing them to become more involved in their treatment, which can result in im‐
proved glycemic control. Patient-directed insulin titration is increasingly important as
health care practitioners often do not have the resources to advise patients with the frequen‐
cy needed to effectively titrate their insulin doses to maintain euglycemia. Optimal patient
empowerment through self-titration regimens is critical for the motivation to reach treat‐
ment targets.
7. Prognosis
The coexistence of both T1D and T2D in an individual should in principle denote an in‐
creased risk for the complications of both diseases [32]. Therefore, it is possible that these
individuals are at higher risk for the microvascular and metabolic complications of T1D and
the macrovascular complications of T2D [18]. This is supported by investigations by Or‐
chard et al [85,92], in the Epidemiology of Diabetes Complications Study, who reported that
patients with T1D who have a positive family history of T2D were at greater risk for cardio‐
vascular disease than those who did not. Furthermore, data from the Diabetes Control and
Complications Trial (DCCT) show that weight gain and central obesity are associated with
insulin resistance, hypertension, and dyslipidemia in T1D [93], and data from Epidemiology
of Diabetes Interventions and Complications (EDIC) Study show that central obesity is an
independent risk factor for incident microalbuminuria in individuals with T1D [94]. Howev‐
er, both DCCT and EDIC follow up studies show that intensive diabetes therapy results in a
uniform, major reduction in (and significant protection from) microvascular disease [95],
even in overweight or obese T1D patients [92]. Thus, there is the need to devise a consensus
treatment regimen that would ensure the best glycemic and metabolic outcome for patients
with double diabetes.
8. Conclusions
The global pandemic of obesity in children and adolescents has resulted in a new expression
of diabetes mellitus known as double diabetes. The entity encompasses the autoimmune
load of T1D and the metabolic load of T2D. There is no consensus on the best therapeutic
modality for this new expression of diabetes mellitus. However, optimal therapeutic options
must address the coexistence of both metabolic and autoimmune components of diabetes
mellitus in the patient. There have also been calls to revise the current classification of diabe‐
tes mellitus to take into account the surging prevalence of double diabetes in children and
adolescents.
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